Apotex Health has a leading position in Canada's pharmaceutical space, and an upcoming loss of patent exclusivity cycle will likely push it even further ahead. ATB Cormark's Frederico Gomes says in a report that the company, which went public last month, offers a mix of resilient organic revenue growth, supported by expansion in the prescription pharmaceuticals and branded consumer health and wellness markets. What's more, Gomes predicts a wave of brand patent expirations are projected to surge across both the U.S. and Canada, and generic drug manufacturers like Apotex are positioned to capture it. ATB Cormark initiates coverage with an outperform rating and a price target of 40 Canadian dollars. Shares are up 4% to C$35.30. (adriano.marchese@wsj.com)